evelo-logo.png
Evelo Biosciences Announces Grant of Inducement Award
September 01, 2022 17:15 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
evelo-logo.png
Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference
September 01, 2022 06:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
evelo-logo.png
Evelo Biosciences Announces Succession Plan
August 11, 2022 06:01 ET | Evelo Biosciences, Inc.
– Simba Gill to transition to Chair of the Board of Directors –– Lord Ara Darzi will become Lead Independent Director –– Board has retained Spencer Stuart for Chief Executive Officer search – ...
evelo-logo.png
Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights
August 11, 2022 06:00 ET | Evelo Biosciences, Inc.
– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end –– Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023 –– Phase...
evelo-logo.png
Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
August 05, 2022 06:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
evelo-logo.png
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
July 18, 2022 06:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
evelo-logo.png
CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
May 12, 2022 10:47 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence...
evelo-logo.png
Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors
April 21, 2022 06:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
evelo-logo.png
Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs
April 14, 2022 06:00 ET | Evelo Biosciences, Inc.
–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022––Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023––Faster release...
evelo-logo.png
Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors
April 06, 2022 06:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) --  Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...